Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome
Completed
- Conditions
- Radiologically Isolated SyndromeMultiple Sclerosis
- Registration Number
- NCT03357887
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
To look at the prognostic value of new biomarkers in CSF and serum for characterisation of multiple sclerosis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Level of Neurofilament in cerebrospinal fluid Baseline ELISA
Level of GFAP in cerebrospinal fluid Baseline ELISA
Level of tumour necrosis factor receptor in cerebrospinal fluid Baseline ELISA
Level of secreted glycoprotein in cerebrospinal fluid Baseline ELISA
- Secondary Outcome Measures
Name Time Method Comparison of the conversion time according to the threshold value of each biomarker for Radiologically Isolated Syndrome patients Baseline Log-rank test
Level of tumour necrosis factor receptor in serum Baseline ELISA
Level of GFAP in serum Baseline ELISA
Level of Neurofilament in serum Baseline ELISA
Level of secreted glycoprotein in serum Baseline ELISA
Compare prognostic value of all four markers of the high risk criteria (age below 37, male, myelitis). Baseline Multivariate analysis
Biomarker levels in CSF and serum in different patient subpopulations (Radiologically Isolated Syndrome, recurrent remittent MS, symptomatic controls, central nervous system inflammatory disease controls, non-inflammatory disease controls) Baseline
Trial Locations
- Locations (1)
CHU Nimes
🇫🇷Nîmes, France